Novo Nordisk (Ozempic)
Acquired
Innovating for the Masses: Novo Nordisk's New Strategy
This chapter examines Novo Nordisk's pivot towards affordable, accessible medications for widespread health issues like obesity, contrasting it with the industry's historical focus on high-cost specialty drugs. It discusses the financial and strategic challenges in pharmaceutical innovation and the impact of rising healthcare costs on the quality of care. The conversation highlights the need for healthcare systems to adapt to prioritize chronic conditions and implement value-based care in a changing healthcare landscape.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
